Japan market entry-arkiv - Biosector Ltd.

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Photorealistic scene of a consultant in a Tokyo meeting room connecting a foreign company with Japanese pharma executives.

by Stefan Sandström

December 11, 2025

Why Japanese Targets Like You, Listen to You – and Still You Don’t Succeed

You fly in, you present, you charm the room. Heads nod. The technical team likes your […]

0

by Stefan Sandström

What AstraZeneca’s AI Strategy in China Means for Global Pharma — and Why Japan is a Better Play

Just now, AstraZeneca is making headlines with a $5.3 billion AI research partnership with China’s […]

0

Abstract illustration representing Japan’s SaMD commercialization ecosystem.

by Stefan Sandström

SaMD Commercialization in Japan: Strategic Opportunities Beyond Approval

Japan is the fourth-largest global medical device market, with its healthcare system actively integrating digital tools […]

0

Illustration of a rejected pharmaceutical batch for import into Japan.

by Stefan Sandström

November 10, 2024

The Essential Guide for Successful Batch Release in Japan

Japan represents one of the world’s most demanding pharmaceutical markets, with rigorous quality standards that go […]

0